Allakos Inc.
Allakos Inc. (ALLK) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ALLK · as of Jun 9, 2026
Key Statistics
Explore Allakos Inc. Data
allk stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 11 · Buy rate: 45.5%
The ALLK analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $109.50, representing +33172.56% upside from the current price of $0.33.
Competitors & Peers
allk competitorsALLK
AGTC
ANGN
ELEV
FRLN
HARPStock Performance
Full HistoryAbout Allakos Inc.
Allakos Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic agents. These treatments are designed to target specific immunomodulatory receptors on immune…
what is allakos inc. · allk stock overview · allakos inc. company profile · who is allakos inc. ceo · allk NASDAQ · allakos inc. headquarters · allakos inc. business segments
About Stock Overview & Key Data
Allakos Inc. (ALLK) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 19, 2018. As of the latest trading session, ALLK stock price is $0.33, with a market capitalization of $29.7M. The stock has returned -71.63% over the past 12 months and -73.46% year-to-date.
According to 11 Wall Street analysts, the consensus rating for Allakos Inc. stock is Buy, with an average 12-month price target of $109.50. In fiscal year 2024, Allakos Inc. reported revenue of — and net income of -$115.8M. For detailed data — including Allakos Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Allakos Inc. (ALLK) stock price is $0.33. The stock is traded on NASDAQ under the ticker symbol ALLK. The 52-week range is $0.22 – $1.56.